Heparina y su contribución al tratamiento del COVID-19
DOI:
https://doi.org/10.33448/rsd-v10i12.20274Palabras clave:
Heparina; Infecciones por coronavirus; Tratamiento farmacológico; Pandemias.Resumen
La infección por SARS-CoV-2 presenta alteraciones en los procesos de coagulación como tromboembolismo venoso (TEV) y coagulación intravascular diseminada (CID) y se ha demostrado que este cuadro de coagulopatía se asocia de alguna manera con la mortalidad. Los estudios sugieren que los anticoagulantes reducen la mortalidad hospitalaria. Sin embargo, los estudios no son demostrativos, ya que se consideran múltiples variables y los resultados obtenidos no son la respuesta a diseños experimentales con variables controladas. En la mayoría de los casos, las respuestas obtenidas son el resultado de casos aislados o modelos experimentales que no mostraron significancia estadística, probablemente por diferencias relacionadas con los grupos de estudio. Sin embargo, en los modelos ajustados por edad y sexo, la reducción de la mortalidad fue estadísticamente significativa en los pacientes tratados con heparina, incluso cuando se añadieron otras variables al modelo. Ante esto, no existe consenso en cuanto a dosis y tipo de anticoagulante entre diferentes países y entidades, pero lo que se cita con mayor frecuencia es el uso de heparina de bajo peso molecular (HBPM) en dosis profiláctica para todos los pacientes hospitalizados por la enfermedad. . El uso de anticoagulantes como las heparinas ha sugerido resultados aplicables al tratamiento de la coagulopatía por COVID-19, lo que hace que el tema sea importante para la centralización y análisis de resultados. Para continuar con la construcción de conocimiento sobre el tema, el objetivo de este trabajo fue realizar una revisión sobre el uso de heparinas en el tratamiento del COVID-19.
Citas
Ageno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E. M. & Palareti, G. (2012). Oral Anticoagulant Therapy. Chest, 141 (2), e44S-e88S. https://doi.org/10.1378/chest.11-2292
Artifoni, M., Danic, G., Gautier, G., Gicquel, P., Boutoille, D., Raffi, F., Néel, A. & Lecomte, R. (2020). Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis, 50 (1), 211–6. https://doi.org/10.1007/s11239-020-02146-z
Ayerbe, L., Risco, C. & Ayis, S. (2020). The association between treatment with heparin and survival in patients with Covid-19. J Thromb Thrombolysis, 50 (2), 298–301. https://doi.org/10.1007/s11239-020-02162-z
Barbar, S., Noventa, F., Rossetto, V., Ferrari, A., Brandolin, B., Perlati, M., Bon, E. de., Tormene, D., Pagnan, A. & Prandoni P. (2010). A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score: Padua Prediction Score. Journal of Thrombosis and Haemostasis, 8 (11), 2450–7. http://dx.doi.org/10.1111/j.1538-7836.2010.04044.x
Barlow, A., Landolf, K. M., Barlow, B., Yeung, S. Y. A., Heavner, J. J., Claassen, C. W. & Heavner, M. S. (2020). Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy, 40 (5), 416–37. https://doi.org/10.1002/phar.2398
Barnes, G. D., Burnett, A., Allen, A., Blumenstein, M., Clark, N. P., Cuker, A., Dager, W. E., Deitelzweig, S. B., Ellsworth, S., Garcia, D., Kaatz, S. & Minichiello, T. (2020). Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis, 50 (1):72–81.https://doi.org/10.1007/s11239-020-02138-z
Barrett, C. D., Moore, H. B., Yaffe, M. B. & Moore, E. E. (2020). ISTH interim guidance on recognition and management of coagulopathy in COVID‐19: A comment. J Thromb Haemost, 18 (8), 2060–3. http://dx.doi.org/10.1111/jth.14860
Bauer, K. A. (2013). Pros and cons of new oral anticoagulants. Hematology. Hematology Am Soc Hematol Educ Program, (1), 464–70. https://doi.org/10.1182/asheducation-2013.1.464
Belen-Apak, F. B. & Sarialioglu, F. (2020). The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases? Medical Hypotheses, 142:109743. https://doi.org/10.1016/j.mehy.2020.109743
Beun, R., Kusadasi, N., Sikma, M., Westerink, J., Huisman, A. (2020) Thromboembolic events and apparent heparin resistance in patients infected with SARS‐CoV‐2. Int J Lab Hematol, 42 (S1), 19–20. http://dx.doi.org/10.1111/ijlh.13230
Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., Der Nigoghossian, C., Ageno, W., Madjid, M., Guo, Y., Tang, L.V., Hu, Y., Giri, J., Cushman, M., Quéré, I., Dimakakos, E. P., Gibson, C. M., Lippi, G., Favaloro, E. J., Fareed, J., Caprini, J. A., Tafur, A. J., Burton, J. R., Francese, D. P., Wang, E. Y., Falanga,A., McLintock, C., Hunt, B. J., Spyropoulos, A. C., Barnes, G. D., Eikelboom, J. W., Weinberg, I., Schulman, S., Carrier, M., Piazza, G., Beckman, J. A., Steg, P. G., Stone, G. W., Rosenkranz, S., Goldhaber, S. Z.,Parikh, S. A., Monreal, M., Krumholz, H. M., Konstantinides, S. V., Weitz, J. I. & Lipfor G. Y. H. (2020). COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 75 (23), 2950–73. https://www.onlinejacc.org/content/75/23/2950
Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S. C. & Di Napoli, R. (2021). Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554776/
Casini, A., Alberio, L., Angelillo-Scherrer, A., Fontana, P., Gerber, B., Graf, L., Inga, H., Wolfang, K., Johanna, A. K. H., Thomas, L., Maria, M., Michael, N., Jan-Dirk, S., Dimitrios, T., Walter, W. & Lars M. A. (2021). Thromboprophylaxis and laboratory monitoring for in-hospital patients with Covid-19 - a Swiss consensus statement by the Working Party Hemostasis. Swiss Med Wkly. https://doi.emh.ch/smw.2020.20247
Cespedes, M. S & Souza, J. C (2020). SARS-CoV-2: uma revisão para o clínico. https://preprints.scielo.org/index.php/scielo/preprint/view/26/version/30
Chan, J. F. W., Kok, K. H, Zhu, Z., Chu, H., To, K. K. W., Yuan, S. & Yuen, K-Y. (2020). Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes & Infections, 9 (1), 221–36. https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1719902
Chousterman, B. G., Swirski, F. K. & Weber, G. F. (2017). Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol, 39 (5), 517–28. https://doi.org/10.1007/s00281-017-0639-8
Conzelmann, C., Müller, J. A., Perkhofer, L., Sparrer. K. M., Zelikin, A. N., Münch, J. & Kleger, A. (2020). Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19. Clin Med, 20 (6), e218–21. https://doi.org/10.7861/clinmed.2020-0351.
Costa. A. L. E., Branco, A. C., Dzik, A., Link, C., Coelho, C. V. F. G., Voget, J. M., Leuzz, L. F. A., Amaral, M. E. B., Badaloti, M., Martins, M. W. P. B., Valadares, N. P. B., Sasb, N. A, Costa, P. T. V., Petracco, R. G., Nogueira, S., Mattiello, S., Resende, S. de S., Dzik, T. E. & Carvalho, W. de A .P. de. (2020). Tratamento Coronavírus. In: Salgueiro LL. Interfaces: Reprodução Humana e Covid-19. Sociedade Brasileira de Reprodução Assistida, 130 -135. https://sbra.com.br/wp-content/uploads/2020/05/SBRA-e-Covid-19.pdf
Costanzo, L., Palumbo, F. P., Ardita, G., Antignani, P. L., Arosio, E. & Failla, G. (2020). Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 8 (5), 711–6. https://doi.org/10.1016/j.jvsv.2020.05.018
Coutard, B., Valle, C., Lamballerie, X. de, Canard, B., Seidah, N. G. & Decroly, E. (2020). The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Research, 176, 104742. https://doi.org/10.1016/j.antiviral.2020.104742
Cui, S., Chen, S., Li, X., Liu, S. & Wang, F. (2020) Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost, 18 (6), 1421–4. http://dx.doi.org/10.1111/jth.14830
Dias, V., Carneiro, M., Vidal, C., Corradi, M., Brandão, D., Cunha, C., Chebabo, A., Oliveira, P. R. D. de, Michelin, L., Rocha, J. L. L., Waib, L. F., Carrilho, C. M., Lobo, S. M. A., Oliveira, M. C.de, Nunes, R. R., Diego,L. A.dos S., Santos, A. S., Muglia, M. V., Souza Jr., A. S.de, Escuissato, D., Neto, C. A., Chatkin, J. M., Martins, R., Maurici, R., Costa, S. F., Alves, J. S., Nascimento, M. M. do. & Moura-Neto, J. A., (2020). Orientações sobre Diagnóstico, Tratamento e Isolamento de Pacientes com COVID-19. J. Infect. Control, 2 (9), 58–77. https://infectologia.org.br/wp-content/uploads/2020/07/orientacoes-sobre-diagnostico-tratamento-e-isolamento-de-pacientes-com-covid-19.pdf
Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Jon, B. C. S., Kevin, D., Jeffrey, F., Kelly G., Ruth H., Yasser K., Maximilian, T., Hugo M., Jens-Uwe, V., Maarten, L. S. & Frans, V. de W. (2013). Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. N Engl J Med, 369 (13):1206–14. DOI: 10.1056/NEJMoa1300615
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J-C., Turner, A. J., Raizada, M. K., Grant, M. B & Oudit, G. Y. (2020). Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res, 126 (10), 1456–74. https://doi.org/10.1161/CIRCRESAHA.120.317015
Harenberg, J. & Favaloro, E. (2020) COVID-19: progression of disease and intravascular coagulation – present status and future perspectives. Clinical Chemistry and Laboratory Medicine (CCLM), 58 (7), 1029–36. https://doi.org/10.1515/cclm-2020-0502
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M. & Guyatt, G. H. (2012). Evidence-Based Management of Anticoagulant Therapy. Chest, 141 (2), e152S-e184S. https://doi.org/10.1378/chest.11-2295
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei,Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J., Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395 (10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
Iba, T. & Levy, J. H. (2018). Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost, 16 (2), 231–41. https://doi.org/10.1111/jth.13911
Jackson, S. P., Darbousset, R. & Schoenwaelder, S.M. (2019). Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood, 133 (9), 906–18. https://doi.org/10.1182/blood-2018-11-882993
Kumar, D., Malviya R. & Sharma P. (2020). Corona Virus: A Review of COVID-19 History and Origin. Eurasian Journal of Medicine and Oncology, 4 (1), 8–25
Klok, F. A., Kruip, M. J. H. A., Van der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., Kaptein, F. H. J., Paassen, J. van., Stals, M. A. M., Huisman, M. V. & Endeman, H. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research, 191, 145–7. https://doi.org/10.1016/j.thromres.2020.04.013
Kreuziger, L., Lee, A., Garcia, D., Cuker, A., Cushman, M., D. S. M. & Connors, J. (2020). American Society of Hematology. COVID-19 and VTE/Anticoagulation: Frequently Asked Questions. American Society Of Hematology. https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation
Lever, R. & Page, C. P. (2012). Non-anticoagulant Effects of Heparin: An Overview. In: Lever R, Mulloy B, Page CP, organizadores. Heparin - A Century of Progress, 281–305. http://link.springer.com/10.1007/978-3-642-23056-1_12
Levi, M., Thachil, J., Iba, T. & Levy, J. H. (2020). Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematology, 7 (6), e438–40. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30145-9/fulltext
Li, L., Huang, T., Wang, Y., Wang, Z., Liang, Y., Huang, T., Zhang, H., Sun, W., Wang, Y. (2020). COVID‐19 patients’ clinical characteristics, discharge rate, and fatality rate of meta‐analysis. J Med Virol, 92 (6), 577–83. https://doi.org/10.1002/jmv.25757
Magro, G. (2020). Cytokine Storm: Is it the only major death factor in COVID-19 patients? Coagulation role. Medical Hypotheses, 142, 109829. https://pubmed.ncbi.nlm.nih.gov/32428809/
Marietta, M. et al. (2020). COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis, SISET. Blood Transfusion. https://doi.org/10.2450/2020.0083-2
Menezes‐Rodrigues, F. S., Tavares, J. G. P., Oliveira. M. P. de, Carvalho, R. G.de, Errante P. R., Taha M. O., Fagundes, D. J. & Caricati-Neto A. (2020). Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID‐19 patients. J Thromb Haemost,18 (8), 2073–5. https://doi.org/10.1111/jth.14902
Mycroft-West, C. J., Su, D., Pagani, I., Rudd, T. R., Elli, S., Guimond, S. E., Miller, G., Meneghetti, M. C. Z, Nader, H. B., Li, Y., Nunes, Q. M., Procter, P., Mancini, N., Clementi, M., Bisio, A., Forsyth, N. R, Turnbull, J. E., Guerrini, M., Fernig, D. G., Vicenzi, E., Yates, E. A., Lima, M. A. & Skidmore, M. A. (2020). Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin. Thromb Haemost, 120 (12):1700–15. https://doi.org/10.1101/2020.04.28.066761
Nascimento, J. H. P., Gomes, B. F. de O., Carmo, P. R. do, Petriz, J. L. F., Rizk, S. I., Costa, I. B. S. da S., Marcus, V. G. L., Fernando, B., Ludhmila, A. H & Gláucia, M. M. de O. (2020). COVID-19 e Estado de Hipercoagulabilidade: Uma Nova Perspectiva Terapêutica. Arquivos Brasileiros de Cardiologia, 114 (5):829–33. https://www.scielo.br/j/abc/a/trcCwg8ncqpMwRgn8Hq7Bbw/?lang=pt
Nicolai, L., Leunig, A., Brambs, S., Kaiser, R., Weinberger, T., Weigand, M., Maximilian, M., Johannes, C. H., Stephan, L., Heiko, S., Clemens, S., Martina, R., Michael, Z., Dominik, H., Oliver K., Daniel, T., Bernhard, Z., Michael, V.B.-B., Stefan, K., Steffen, M., Kami & P., Konstantin S. (2020). Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy. Circulation, 142 (12):1176–89. https://doi.org/10.1161/CIRCULATIONAHA.120.048488
Nissborg, E., Wahlgren, C-M. (2019). Anticoagulant Effect of Standard Dose Heparin During Peripheral Endovascular Intervention. Annals of Vascular Surgery, 60:286–92. https://doi.org/10.1016/j.avsg.2019.02.033
Obi, A. T., Barnes, G. D., Wakefield, T. W., Brown, S., Eliason, J. L., Arndt, E. & Henke, P. K. (2020). Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 pandemic. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 8 (4):526–34. https://doi.org/10.1016/j.jvsv.2020.04.009
Obi, A. T., Tignanelli, C. J., Jacobs, B. N., Arya S., Park, P. K., Wakefiel, T. W., Henke, P. K. & Napolitano, L. M. (2019). Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 7 (3), 317–24. https://doi.org/10.1016/j.jvsv.2018.08.010
Orsi, F. A., Paula, E. V.de, Santos, F.de O., Teruchkin, M. M., Campêlo, D. H. C., Mello, T. T., Chindamohi, M. C., Macedo, A. V. S., Rocha, A. T., Ramacciottino, E., Nascimento, A. C. K., Annichino-Bizzacchi, J., Lourenco, D. M., Guerra, J. C, de C., Rezendes, S. M. & Filho, C. C. (2020). Guidance on diagnosis, prevention and treatment of thromboembolic complications in COVID-19: a position paper of the Brazilian Society of Thrombosis and Hemostasis and the Thrombosis and Hemostasis Committee of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy. Hematology, Transfusion and Cell Therapy, 42 (4), 300–8. https://doi.org/10.1016/j.htct.2020.06.001
Poggiali, E.,Bastoni, D., Bastoni, E., Vercelli, A. & Magnacavallo A. (2020). Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia? European Journal of Case Reports in Internal Medicine, 7 (5), 1. https://doi.org/10.12890/2020_001646
Porfidia, A. & Pola, R. (2020). Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines. J Thromb Thrombolysis, 50 (1), 68–71. https://doi.org/10.1007/s11239-020-02125-4
Ranucci, M., Ballotta, A., Di Dedda, U., Bayshnikova, E., Dei Poli, M., Resta, M., Falco, M., Albano, G. & Menicanti, L. (2020). The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome. J Thromb Haemost, 18 (7), 1747–51. https://doi.org/10.1111/jth.14854
Soeiro, A. de M., Leal, T. de C.A.T., Pereira, M. de P., Lima, E. G., Figueiredo, A. C. B. da S., Petriz, J. L. F., Precoma, D. B. & Serrano, C. V. J. (2020). Posicionamento sobre Uso de Antiplaquetários e Anticoagulantes nos Pacientes Infectados pelo Novo Coronavírus (COVID-19) – 2020. Arquivos Brasileiros de Cardiologia, 115 (2):292–301. https://doi.org/10.36660/abc.20200424
Sociedad Española de Trombosis y Hemostasia (2020). Recomendaciones de Tromboprofilaxis Y Tratamiento Antitrombótico em Pacientes con COVID-19. http://www.fasgo.org.ar/index.php/informacion-a-la-comunidad/2032-recomendaciones-de-tromboprofilaxis-y-tratamiento-antitrombotico-en-pacientes-con-covid-19
Shi, C., Wang, C., Wang, H., Yang, C., Cai, F., Zeng, F., Cheng, F., Liu, Y., Zhou, T., Deng, B., Vlodavsky, I., Li, J-P. & Zhang, Y. (2021). The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study. Pharmacology and Therapeutics. http://medrxiv.org/lookup/doi/10.1101/2020.03.28.20046144
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., Sinnaeve, P., Collins, R., Camm, A.J & Heidbüchel, H. (2018). The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal, 39 (16), 1330–93. https://doi.org/10.1093/eurheartj/ehy136
Stoneham, S. M., Milne, K. M., Nuttall, E., Frew, G. H., Sturrock, B.R., Sivaloganathan H., Ladikou, E.E., Drage, S., Phillips, B., Chevassut, T. J. T. & Eziefula, A. C. (2020). Thrombotic risk in COVID-19: a case series and case–control study. Clin Med, 20 (4), e76–81. https://doi.org/10.7861/clinmed.2020-0228
Tang, N., Bai, H., Chen, X., Gong, J., Li, D. & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost, 18 (5), 1094–9. https://doi.org/10.1111/jth.14768
Tang, N, Li, D., Wang, X. & Sun, Z. (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 18 (4), 844–7. https://doi.org/10.1016/S0140-6736(20)30183-5
Testa, S., Paoletti, O., Giorgi-Pierfranceschi, M. & Pan, A. (2020). Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients. Intern Emerg Med, 15 (5), 751–3. https://doi.org/10.1007/s11739-020-02331-1
Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., Clark, C. & Iba, T. (2020a). ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost, 18 (5), 1023–6. https://pubmed.ncbi.nlm.nih.gov/32338827/
Thachil, J., Tang, N., Gando, S., Falanga, A., Levi, M., Clark, C., Iba, T. & Cattaneo, M. (2020b). Type and dose of heparin in Covid‐19: Reply. J Thromb Haemost, 18 (8), 2063–4. https://doi.org/10.1111/jth.14870
Thachil, J. (2020). The versatile heparin in COVID‐19. J Thromb Haemost, 18 (5):1020–2. https://doi.org/10.1111/jth.14821.
Vivas, D., Roldán, V., Esteve-Pastor, M. A., Roldán, I., Tello-Montoliu, A., Ruiz-Nodar, J. M., Cosín-Sales, J., Gámez, J. M., Consuegrai, L., Ferreiro, J. L. & Marín, F. (2020). Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología. Revista Española de Cardiología, 73 (9), 749–57. https://doi.org/10.1016/j.recesp.2020.04.006
Wang, T., Chen, R., Liu, C., Liang, W., Guan, W., Tang, R., Nanshan, Z & Shiyue, L. (2020). Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. The Lancet Haematology, 7 (5), e362–3. https://doi.org/10.1016/S2352-3026(20)30109-5
Wichmann, D., Sperhake, J-P., Lütgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F., Mushumba, H., Kniep, I., Schröder, A.S., Burdelski, C., Heer, G. de, Nierhaus, A., Frings, D., Pfefferle, S., Becker, H., Bredereke-Wiedling, H., Weerth, A. de, Paschen, H-R., Sheikhzadeh-Eggers, S., Stang, A., Schmiedel, S., Bokemeyer, C., Addo, M.M., Aepfelbacher, M., Püschel, K., Kluge, S. (2020). Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Annals of Internal Medicine, 173 (4), 268–77. https://doi.org/10.7326/M20-2003
World Health Organization (2021). Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019?adgroupsurvey={adgroupsurvey}&gclid=Cj0KCQjw1dGJBhD4ARIsANb6OdnD82y64IhGz6IJ5RrinIPSHNqAQSNw7CGfvutKsbIROpFAqgmyaK8aAp5lEALw_wcB
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., Zhang, Y., Song, J., Wang, S., Chao, Y., Yang, Z., Xu, J., Zhou, X., Chen, D., Xiong, W., Xu, L., Zhou, F., Jiang, J., Bai, C., Zheng J. & Song Y. (2020). Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med, 180 (7), 934. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184
Whitlock, R. P., Sun, J. C., Fremes, S. E., Rubens, F. D., Teoh, K. H. (2012). Antithrombotic and Thrombolytic Therapy for Valvular Disease. Chest, 141 (2), e576S-e600S. https://doi.org/10.1378/chest.11-2305
Whyte, C. S., Morrow, G. B., Mitchell, J. L., Chowdary, P., Mutch, N. J. (2020). Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19. J Thromb Haemost, 18 (7):1548–55. https://doi.org/10.1111/jth.14872
Ye, Q., Wang, B. & Mao, J. (2020) The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. Journal of Infection, 80 (6), 607–13. https://doi.org/10.1016/j.jinf.2020.03.037
Yin, S., Huang, M., Li, D. & Tang, N. (2020). Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis, 1-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7124128/
Yuki, K., Fujiogi, M. & Koutsogiannaki S. (2020). COVID-19 pathophysiology: A review. Clinical Immunology, 215:108427. https://doi.org/10.1016/j.clim.2020.108427
Zehnder, J. L.(2017). Fármacos usados nos distúrbios de coagulação. In: Katzung, B.G., Trevor, A.J.,.Farmacologia básica e clínica. 13th ed., AMGH, Porto Alegre.
Zheng, Y. Y., Ma, Y. T., Zhang, J. Y & Xie X. (2020). COVID-19 and the cardiovascular system. Nat Rev Cardiol, 17 (5), 259–60. https://doi.org/10.1038/s41569-020-0360-5
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L.,Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 395 (10229), 1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2021 Tamíres Hillesheim Mittelmann; Juliana Baldissera Dors; Victória Galletti dos Santos Arraes; Graciela Soares Fonseca; Cesar Andres Diaz Arias
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores que publican en esta revista concuerdan con los siguientes términos:
1) Los autores mantienen los derechos de autor y conceden a la revista el derecho de primera publicación, con el trabajo simultáneamente licenciado bajo la Licencia Creative Commons Attribution que permite el compartir el trabajo con reconocimiento de la autoría y publicación inicial en esta revista.
2) Los autores tienen autorización para asumir contratos adicionales por separado, para distribución no exclusiva de la versión del trabajo publicada en esta revista (por ejemplo, publicar en repositorio institucional o como capítulo de libro), con reconocimiento de autoría y publicación inicial en esta revista.
3) Los autores tienen permiso y son estimulados a publicar y distribuir su trabajo en línea (por ejemplo, en repositorios institucionales o en su página personal) a cualquier punto antes o durante el proceso editorial, ya que esto puede generar cambios productivos, así como aumentar el impacto y la cita del trabajo publicado.
